Newmark Healthcare Capital Markets Group Continues its Expansion with Three New Roles 

Newmark announces its Healthcare Capital Markets Group has expanded the team, hiring Chad Prescher as Associate Director and promoting Ron Ott and Conor Hilton to Associate Director and Associate, respectively. Led by Executive Managing Director Ben Appel, Senior Managing Directors Jay MieleMichael Greeley and John Nero, Newmark’s Healthcare Capital Markets Group specializes in medical outpatient building (MOB) sales, equity placement and joint venture formation, debt placement and health system monetization and RFP transactions. 

“In spite of the macroeconomic headwinds, our team continues to invest in our most valuable resource, our people. Our client-forward approach that we bring to our services each day remains priority number one, so making sure that we have the right people in the right seats is key,” said Appel. “Through this dedication, our team has achieved growth and many successes, which, in turn, has resulted in our ability to expand with the welcoming of Ron’s transition into a production role as well as the onboarding of Chad and Conor.” 

As Associate Director, Prescher focuses on executing the team’s business activities on behalf of healthcare real estate owners, capital allocators, developers and health systems, including investment sales, debt and equity placements, development advisory and hospital monetization. 

During his career, Ott has been involved in more than 75 transactions with an aggregate value exceeding $5 billion. In expanding his scope into a brokerage and advisory role, Ott will leverage the deep relationships, transaction and advisory experience he has gained to focus on the team’s real estate activities. His expertise includes advising developers, operating partners, capital providers and health systems in portfolio strategy, asset monetization, investment sales and financings, debt and equity placements and development advisory. After several years at HFF and JLL, Ott joined Newmark in 2020, where he has been integral to the firm’s National Healthcare Capital Markets Group’s transaction activity. 

Initially serving as a consulting analyst, Hilton transitioned to the firm’s Healthcare Capital Markets Group in early 2023. In his new role as Associate, Hilton specializes in underwriting and financial analysis for both single asset and portfolio transactions.  

“Ron’s deep knowledge of MOB underwriting and sector participants will serve him well in his new role, one in which he will undoubtedly be successful,” said Miele. “The immense healthcare real estate transaction experience that Chad and Conor bring to our team will further bolster our capacity to serve our existing and new clients.” 

With a combined 75 years of total healthcare real estate experience, the team has completed strategic joint ventures, sales and recapitalizations, as well as debt and structured financing activity totaling approximately $12.8 billion since its formation in 2021. Operations and Transactions Manager Caroline Hoffman and Senior Graphic Designer Anthony Faggiola support the team.  

About Newmark  

Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark’s comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform’s global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the year ending December 31, 2022, Newmark generated revenues of approximately $2.7 billion. As of September 30, 2023, Newmark’s company-owned offices, together with its business partners, operate from approximately 170 offices with 7,400 professionals around the world. To learn more, visit or follow @newmark

Discussion of Forward-Looking Statements about Newmark 

Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the effects of the COVID-19 pandemic on the Company’s business, results, financial position, liquidity and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.